Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.6K

Depression in adult patients with biotin responsive basal ganglia disease

Dalal K Bubshait1, Asif Rashid, Mohammed A Al-Owain

  • 1Department of Medical Genetics, King Faisal Specialist Hospital and Research center.

Drug Discoveries & Therapeutics
|August 19, 2016
PubMed

Insights

Biotin responsive basal ganglia disease (BBGD) is treatable, but long-term outcomes are unknown. Treated BBGD patients may develop depression later in life, indicating a potential chronic complication.

Area of Science:

  • Neurology
  • Metabolic Disorders
  • Genetics

Background:

  • Biotin responsive basal ganglia disease (BBGD) is an inherited metabolic disorder.
  • Early diagnosis and treatment lead to good childhood recovery.
  • Long-term outcomes in treated adult patients remain underreported.

Observation:

  • Two adult patients with BBGD, stable on treatment, developed depression.
  • This suggests a potential link between BBGD and mood disorders.

Findings:

  • Depression can manifest as a long-term complication in individuals with BBGD.
  • The study highlights the importance of monitoring mental health in treated BBGD patients.

Implications:

  • This research underscores the need for comprehensive, long-term follow-up of BBGD patients.
  • It suggests that neurological and psychiatric monitoring should be integral to managing BBGD throughout life.
  • Further research is warranted to understand the mechanisms linking BBGD and late-onset depression.

More Related Videos

Assessment of Long-term Depression Induction in Adult Cerebellar Slices09:30

Assessment of Long-term Depression Induction in Adult Cerebellar Slices

Published on: October 16, 2019

7.4K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

23.2K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K